{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:43:57Z","timestamp":1795045437173,"version":"4.10.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T00:00:00Z","timestamp":1577491200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["5189-00040B"],"award-info":[{"award-number":["5189-00040B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Compounds in clinical development for nonalcoholic steatohepatitis (NASH) improve liver histopathology in diet-induced obese mouse models of biopsy-confirmed NASH. Since the biopsy section used for histopathological evaluation represents only &lt;\u20091% of the whole mouse liver, we evaluated how well biopsy-based quantitative image analyses correlate to stereology-based whole-liver quantitative changes upon drug treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Male leptin-deficient <jats:italic>Lep<\/jats:italic><jats:sup><jats:italic>ob<\/jats:italic><\/jats:sup><jats:italic>\/Lep<\/jats:italic><jats:sup><jats:italic>ob<\/jats:italic><\/jats:sup> mice were fed the Amylin liver NASH (AMLN) diet for 16\u2009weeks before stratification into treatment groups using a biopsy-based evaluation of type I collagen \u03b1I (col1a1) levels. Mice were treated for 8\u2009weeks with either vehicle (PO, QD), liraglutide (0.4\u2009mg\/kg, SC, QD), elafibranor (30\u2009mg\/kg, PO, QD) or INT-767 (10\u2009mg\/kg, PO, QD). Terminal quantitative histological assessment of liver lipid (hematoxylin-eosin staining), inflammation (galectin-3 immunohistochemistry (IHC); gal-3), and fibrosis (col1a1 IHC) was performed on terminal liver biopsies and compared with stereologically sampled serial sections spanning the medial, left and right lateral lobe of the liver.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The distribution of liver lipid and fibrosis was markedly consistent across lobes, whereas inflammation showed some variability. While INT-767 and liraglutide significantly reduced total liver weight by 20 and 48%, respectively, elafibranor tended to exacerbate hepatomegaly in <jats:italic>Lep<\/jats:italic><jats:sup><jats:italic>ob<\/jats:italic><\/jats:sup><jats:italic>\/Lep<\/jats:italic><jats:sup><jats:italic>ob<\/jats:italic><\/jats:sup>-NASH mice. All three compounds markedly reduced biopsy-based relative liver lipid content. Elafibranor and INT-767 significantly reduced biopsy-based relative gal-3 levels (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), whereas INT-767 and liraglutide tended to reduce relative col1a1 levels. When changes in liver weight was accounted for, both INT-767 and liraglutide significantly reduced biopsy-based total col1a1 content. Although minor differences in absolute and relative liver lipid, inflammation and fibrosis levels were observed across lobes, the interpretation of drug-induced effects were consistent with biopsy-based conclusions. Notably, the incorporation of changes in total liver mass revealed that liraglutide\u2019s efficacy reached statistical significances for all analyzed parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, in-depth analyses of liver homogeneity demonstrated that drug-induced improvement in liver biopsy-assessed histopathology is representative for overall liver effects assessed using stereology. Importantly, these findings reveal how changes in whole-liver mass should be considered to provide a deeper understanding of apparent drug treatment efficacy in preclinical NASH studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-019-1149-z","type":"journal-article","created":{"date-parts":[[2019,12,28]],"date-time":"2019-12-28T13:02:30Z","timestamp":1577538150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH"],"prefix":"10.1186","volume":"19","author":[{"given":"Maria Nicoline","family":"Baandrup Kristiansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Skovg\u00e5rd","family":"Veidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan David","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Adorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4583-1022","authenticated-orcid":false,"given":"Jacob","family":"Jelsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,28]]},"reference":[{"key":"1149_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cld.2004.06.008","volume":"8","author":"SA Harrison","year":"2004","unstructured":"Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2004;8:861\u201379.","journal-title":"Clin Liver Dis"},{"key":"1149_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1463-1326.2011.01403.x","volume":"13","author":"JK Dowman","year":"2011","unstructured":"Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab. 2011;13:692\u2013702.","journal-title":"Diabetes Obes Metab"},{"key":"1149_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","volume":"42","author":"LA Adams","year":"2005","unstructured":"Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132\u20138.","journal-title":"J Hepatol"},{"key":"1149_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","volume":"10","author":"A Wree","year":"2013","unstructured":"Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627\u201336.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1149_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.13301","volume":"37","author":"P Bedossa","year":"2016","unstructured":"Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2016;37:85\u20139.","journal-title":"Liver Int"},{"key":"1149_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/hep.23521","volume":"51","author":"P Angulo","year":"2010","unstructured":"Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance. Hepatology. 2010;51:373\u20135.","journal-title":"Hepatology"},{"key":"1149_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","volume":"256","author":"VG Agopian","year":"2012","unstructured":"Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg. 2012;256:624\u201333.","journal-title":"Ann Surg"},{"key":"1149_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"1149_CR9","first-page":"264","volume":"6","author":"JJ Connolly","year":"2018","unstructured":"Connolly JJ, Ooka K, Lim JK. Future pharmacotherapy for non-alcoholic Steatohepatitis (NASH): review of phase 2 and 3 trials. Hournal Clin Transl Hepatol. 2018;6:264\u201375.","journal-title":"Hournal Clin Transl Hepatol"},{"key":"1149_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2050-7771-1-7","volume":"1","author":"SG Pearce","year":"2013","unstructured":"Pearce SG, Thosani NC, Pan J-J. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7.","journal-title":"Biomark Res"},{"key":"1149_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VWS Wong","year":"2018","unstructured":"Wong VWS, Adams LA, de L\u00e9dinghen V, Wong GLH, Sookoian S. Noninvasive biomarkers in NAFLD and NASH \u2014 current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461\u201378. https:\/\/doi.org\/10.1038\/s41575-018-0014-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1149_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2008.10.014.","journal-title":"J Hepatol"},{"key":"1149_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.hepres.2005.09.006","volume":"33","author":"EM Brunt","year":"2005","unstructured":"Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:68\u201371.","journal-title":"Hepatol Res"},{"key":"1149_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.humpath.2011.07.007","volume":"43","author":"CD Guy","year":"2012","unstructured":"Guy CD, Suzuki A, Burchette JL, Brunt EM, Abdelmalek MF, Cardona D, et al. Costaining for keratins 8\/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol. 2012;43:790\u2013800.","journal-title":"Hum Pathol"},{"issue":"2 Suppl. 1","key":"1149_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/hep.20973","volume":"43","author":"GC Farrell","year":"2006","unstructured":"Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl. 1):99\u2013112.","journal-title":"Hepatology"},{"key":"1149_CR16","doi-asserted-by":"publisher","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","volume":"20","author":"Y Takahashi","year":"2014","unstructured":"Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:15539\u201348.","journal-title":"World J Gastroenterol"},{"key":"1149_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","volume":"65","author":"Y Fazel","year":"2016","unstructured":"Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017\u201325. https:\/\/doi.org\/10.1016\/j.metabol.2016.01.012.","journal-title":"Metabolism"},{"key":"1149_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-60327-194-3_6","volume":"593","author":"U Ariz","year":"2010","unstructured":"Ariz U, Mato JM, Lu SC, Mart ML. Nonalcoholic Steatohepatitis, animal models, and biomarkers: what is new? Methods Mol Biol. 2010;593:109\u201336.","journal-title":"Methods Mol Biol"},{"key":"1149_CR19","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen HH, Feigh M, Veidal SS, Rigbolt KTG, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707\u201318. https:\/\/doi.org\/10.1016\/j.drudis.2017.06.007.","journal-title":"Drug Discov Today"},{"key":"1149_CR20","doi-asserted-by":"publisher","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","volume":"302","author":"JL Trevaskis","year":"2012","unstructured":"Trevaskis JL, Griffin PS. Wittmer C, Neuschwander-Tetri B a., Brunt EM, Dolman CS, et al. glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. AJP Gastrointest Liver Physiol. 2012;302:G762\u201372.","journal-title":"AJP Gastrointest Liver Physiol"},{"key":"1149_CR21","doi-asserted-by":"publisher","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","volume":"305","author":"JR Clapper","year":"2013","unstructured":"Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol. 2013;305:G483\u201395.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1149_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.00001","volume":"9","author":"Z-M Ding","year":"2018","unstructured":"Ding Z-M, Xiao Y, Wu X, Zou H, Yang S, Shen Y, et al. Progression and regression of hepatic lesions in a mouse model of NASH induced by dietary intervention and its implications in pharmacotherapy. Front Pharmacol. 2018;9:1\u201315.","journal-title":"Front Pharmacol"},{"key":"1149_CR23","first-page":"E484","volume":"310","author":"RE Patterson","year":"2016","unstructured":"Patterson RE, Kalavalapalli S, Williams CM, Nautiyal M, Mathew JT, Martinez J, et al. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. Am J Physiol Metab. 2016;310:E484\u201394.","journal-title":"Am J Physiol Metab"},{"key":"1149_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41598-018-36862-7","volume":"9","author":"E Kawashita","year":"2019","unstructured":"Kawashita E, Ishihara K, Nomoto M, Taniguchi M, Akiba S. A comparative analysis of hepatic pathological phenotypes in C57BL\/6J and C57BL\/6N mouse strains in non-alcoholic steatohepatitis models. Sci Rep. 2019;9:204.","journal-title":"Sci Rep"},{"key":"1149_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","volume":"8","author":"MNB Kristiansen","year":"2016","unstructured":"Kristiansen MNB, Veidal SS, Rigbolt KTG, T\u00f8lb\u00f8l KS, Roth JD, Jelsing J, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol. 2016;8:673\u201384.","journal-title":"World J Hepatol"},{"key":"1149_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l KS, Kristiansen MNB, Hansen HH, Veidal SS, Rigbolt KTG, Gillum MP, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24:179\u201394.","journal-title":"World J Gastroenterol"},{"key":"1149_CR27","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","volume":"6","author":"H Jouihan","year":"2017","unstructured":"Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, et al. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Mol Metab. 2017;6:1360\u201370.","journal-title":"Mol Metab"},{"key":"1149_CR28","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3748\/wjg.v24.i16.1748","volume":"24","author":"ML Boland","year":"2018","unstructured":"Boland ML, Oldham S, Boland BB, Will S, Lapointe J-M, Guionaud S, et al. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction. World J Gastroenterol. 2018;24:1748\u201365.","journal-title":"World J Gastroenterol"},{"key":"1149_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","volume":"24","author":"JD Roth","year":"2018","unstructured":"Roth JD, Feigh M, Veidal SS, Fensholdt LKD, Rigbolt KT, Hansen HH, et al. INT-767 improves histopathological features in a dietinduced Ob\/Ob mouse model of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24:195\u2013210.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"1149_CR30","doi-asserted-by":"publisher","first-page":"e25269","DOI":"10.1371\/journal.pone.0025269","volume":"6","author":"Shvetank Sharma","year":"2011","unstructured":"Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011;6.","journal-title":"PLoS ONE"},{"key":"1149_CR31","doi-asserted-by":"publisher","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","volume":"302","author":"JE Mells","year":"2012","unstructured":"Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet. Am J Physiol Liver Physiol. 2012;302:G225\u201335. https:\/\/doi.org\/10.1152\/ajpgi.00274.2011.","journal-title":"Am J Physiol Liver Physiol"},{"key":"1149_CR32","doi-asserted-by":"publisher","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","volume":"288","author":"RH McMahan","year":"2013","unstructured":"McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013;288:11761\u201370.","journal-title":"J Biol Chem"},{"key":"1149_CR33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039.","journal-title":"J Hepatol"},{"key":"1149_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","volume":"179","author":"N Tanaka","year":"2017","unstructured":"Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017;179:142\u201357.","journal-title":"Pharmacol Ther"},{"key":"1149_CR35","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"1149_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150:1147\u20131159.e5.","journal-title":"Gastroenterology"},{"key":"1149_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","volume":"4","author":"G Svegliati-Baroni","year":"2011","unstructured":"Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, de Minicis S, Candelaresi C, et al. Glucagon-like peptide-1receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;4:1285\u201397.","journal-title":"Liver Int"},{"key":"1149_CR38","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"1149_CR39","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1469-7580.2010.01285.x","volume":"217","author":"SJ Paulsen","year":"2010","unstructured":"Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, Jelsing J. Stereological assessment of pancreatic beta-cell mass development in male Zucker diabetic fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat. 2010;217:624\u201330.","journal-title":"J Anat"},{"key":"1149_CR40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1679\/aohc.51.473","volume":"51","author":"O Ohtani","year":"1988","unstructured":"Ohtani O. Three-dimensional organization of the collagen fibrillar framework of the human and rat livers. Arch Histol Cytol. 1988;51:473\u201388.","journal-title":"Arch Histol Cytol"},{"key":"1149_CR41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0014-4800(89)90061-0","volume":"50","author":"RJ Buschmann","year":"1989","unstructured":"Buschmann RJ, Ryoo JW. Hepatic structural correlates of liver fibrosis: a morphometric analysis. Exp Mol Pathol. 1989;50:114\u201324.","journal-title":"Exp Mol Pathol"},{"key":"1149_CR42","doi-asserted-by":"publisher","first-page":"056007","DOI":"10.1117\/1.3490414","volume":"15","author":"Y He","year":"2010","unstructured":"He Y, Kang CH, Xu S, Tuo X, Trasti S, Tai DCS, et al. Toward surface quantification of liver fibrosis progression. J Biomed Opt. 2010;15:056007. https:\/\/doi.org\/10.1117\/1.3490414.","journal-title":"J Biomed Opt"},{"key":"1149_CR43","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1073\/pnas.0511167103","volume":"103","author":"NC Henderson","year":"2006","unstructured":"Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci. 2006;103:5060\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"1149_CR44","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/jpet.114.218370","volume":"351","author":"L Li","year":"2014","unstructured":"Li L, Li J, Gao J. Functions of Galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351:336\u201343.","journal-title":"J Pharmacol Exp Ther"},{"key":"1149_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/osp4.84","volume":"3","author":"A Mehta","year":"2017","unstructured":"Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management : a critical review of the evidence obesity science & practice. Obes Sci Pract. 2017;3:3\u201314.","journal-title":"Obes Sci Pract"},{"key":"1149_CR46","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51:1584\u201392.","journal-title":"Hepatology"},{"key":"1149_CR47","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of Incretins : GLP-1 and GIP. Gastroenterology. 2007;132:2131\u201357.","journal-title":"Gastroenterology"},{"key":"1149_CR48","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3748\/wjg.v22.i8.2512","volume":"22","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, et al. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J Gastroenterol. 2016;22:2512\u201323.","journal-title":"World J Gastroenterol"},{"key":"1149_CR49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","volume":"20","author":"MM Aranha","year":"2008","unstructured":"Aranha MM, Cortez-Pinto H, Costa A, Da Silva IBM, Camilo ME, De Moura MC, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20:519\u201325.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"1149_CR50","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/MEG.0b013e328345c8c7","volume":"23","author":"S Dasarathy","year":"2011","unstructured":"Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennet C, Kalhan SC. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23(5):382\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1149_CR51","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hep.26225","volume":"57","author":"LP Bechmann","year":"2013","unstructured":"Bechmann LP, Kocabayoglu P, Sowa J-P, Sydor S, Best J, Schlattjan M, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology. 2013;57:1394\u2013406.","journal-title":"Hepatology"},{"key":"1149_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/info8010036","volume":"8","author":"M Tsiplakidou","year":"2017","unstructured":"Tsiplakidou M, Tsipouras MG, Giannakeas N, Tzallas AT, Manousou P. Automated detection of liver Histopathological findings based on biopsy image processing. Information. 2017;8:1\u201312.","journal-title":"Information"},{"key":"1149_CR53","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s10620-018-5395-7","volume":"64","author":"KS T\u00f8lb\u00f8l","year":"2019","unstructured":"T\u00f8lb\u00f8l KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Sch\u00f6nberger T, et al. Disease progression and pharmacological intervention in a nutrient - deficient rat model of nonalcoholic Steatohepatitis. Dig Dis Sci. 2019;64:1238\u201356. https:\/\/doi.org\/10.1007\/s10620-018-5395-7.","journal-title":"Dig Dis Sci"},{"key":"1149_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3346\/jkms.2019.34.e14","volume":"34","author":"YJ Chae","year":"2019","unstructured":"Chae YJ, Jun DW, Saeed WK, Kang HT, Oh JH, Lee SM, et al. Feasibility and stability of liver biopsy before treatment for preclinical nonalcoholic fatty liver studies. J Korean Med Sci. 2019;34:1\u201311.","journal-title":"J Korean Med Sci"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1149-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,27]],"date-time":"2020-12-27T00:05:06Z","timestamp":1609027506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1149-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1149-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"26 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal handling, treatments and euthanization were carried out according to the protocol approved by the Danish National Agency for Protection of Experimental Animals using internationally accepted principles for the care and use of laboratory animals (licence no. 2013-15-2934-00784, The Animal Experiments Inspectorate, Denmark).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MNBK, SSV, MF, NV, and JJ are fulltime employees at Gubra Aps. JDR, ME, and LA are full-time employees at Intercept Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}